Previous 10 | Next 10 |
2019 saw a major milestone year for Sesen Bio ( SESN ) with Type C CMC Meeting, Type B clinical pre-bla meeting, Type C confirmatory trial meeting, Type B cmc pre-bla meeting, obtaining small business exemption and starting the BLA submission under rolling review. Outside of the large spike in...
The following slide deck was published by Sesen Bio, Inc. in conjunction with this Read more ...
Gainers: Mirum Pharmaceuticals (NASDAQ: MIRM ) +110% . More news on: Mirum Pharmaceuticals, Inc., Axsome Therapeutics, Inc., The Goldfield Corporation, Stocks on the move, Read more ...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on December 6, 2019, the Company initiated the submission of its Biologics License Application (BLA) for Vicinium for the t...
Aurinia Pharmaceuticals (NASDAQ: AUPH ) +102% as voclosporin successful in late-stage lupus nephritis study. More news on: Aurinia Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc., SeaChange International, Inc., Stocks on the move, Read more ...
Sesen Bio (NASDAQ: SESN ) is up 9.2% postmarket after reporting a successful Chemistry, Manufacturing and Controls meeting with the FDA over Vicinium. More news on: Sesen Bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Company gained FDA alignment on the final content of the BLA Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported the successful completion of a constructive Type B pre-BL...
Paringa Resources (NASDAQ: PNRL ) -45% . More news on: Paringa Resources Limited, Senseonics Holdings, Inc., Sesen Bio, Inc., Stocks on the move, Read more ...
Senseonics ( SESN ) Q3 results : Revenues: $4.3M (-17.3%). More news on: Sesen Bio, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
The following slide deck was published by Sesen Bio, Inc. in conjunction with their 2019 Q3 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...